Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

Inclusion Criteria:

• Mild stable allergic asthma
• Positive skin-prick test to at least one common aeroallergen
• Positive methacholine challenge
• Positive allergen-induced early- and late-phase airway bronchoconstriction
• General good health

Exclusion Criteria:

• Lung diseases other than mild allergic asthma
• History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
• Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
• Use of tobacco products within one year starting study or smoking history >10 pack years
• If female, pregnant or lactating or have positive pregnancy test at screening